© 1983 Oxford University Press
research-article |
Toxicologic and Carcinogenic Evaluation of Fenvalerate1 in the B6C3F1 Mouse,2
3Toxicology Research, Shell Development Company P.O. Box 822, Houston, TX 77001 4Shell Toxicology Laboratory (Tunstall), Shell Research Ltd. Sittingbourne, Kent, ME9 8AG, United Kingdom 5Department of Toxicology, Litton Bionetics, Inc. 5516 Nicholson Lane, Kensington, MD 20795
Toxicologic and Carcinogenic Evaluation of Fenvalerate in the B6C3F1 Mouse. Parker, C.M., McCullough, C.B., Gellatly, J.B.M. and Johnston, C.D. (1983). Fundam. Appl. Toxicol. 3:114-120. Groups of 50 male and 50 female B6C3F1 mice were fed dietary concentrations of 10, 50, 250 or 1250 ppm Fenvalerate for 2 years. Two groups of control mice, 50 per sex per group, received basal diet only. Mortality was increased and body weight was significantly decreased in male and female mice in the 1250 ppm treatment group. Mean body weight of female mice in the 250 ppm group was also generally lower than controls after the 60th week of feeding. Decreased albumin and increased glutamic oxaloacetic transaminase levels in mice fed 1250 ppm Fenvalerate were the only effects observed in the hematology and serum chemistry parameters examined. The only treatment related non-neoplastic pathologic effect observed in the study was multifocal microgranulomata in lymph nodes, liver and spleen of 1250 ppm male mice and 250 and 1250 ppm female mice. Less severe microgranulomatous changes were present in mesenteric lymph nodes of 50 and 250 ppm male mice. No statistically significant differences were observed in either the number or type of neoplasms in mice fed Fenvalerate diets when compared to concurrent controls. Thus, Fenvalerate was found not to be carcinogenic in B6C3F1 mice under the conditions of the test.